findmyKOL
Clinical trialNCT03722576CompletedPhase 2Interventional

Vidofludimus Calcium for Primary Sclerosing Cholangitis

SponsorElizabeth CareyEnrollment18Primary Sclerosing Cholangitis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To examine the safety, tolerability, and efficacy of daily dosing with vidofludimus calcium over a 6-month period.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic in Arizona

    Phoenix, Arizona, United States

  • Arizona State University

    Tempe, Arizona, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Vidofludimus calcium
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Jun 2019
Primary completion
30 Jun 2020
Completion
30 Jun 2020
Last update posted
17 Oct 2022
Registered enrollment
18
Registry id
NCT03722576
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.